Document is current
Any future updates will be listed below
-
Authors
Krieger, Britta https://orcid.org/0000-0002-6364-2743
Schneider-Gold, Christiane
Genç, Erhan
Güntürkün, Onur
Prehn, Christian
Bellenberg, Barbara
Lukas, Carsten
-
Funding
Funding for this research was provided by:
Ruhr-Universität Bochum
- License Information
-
More Information
Article History
Received: 17 July 2025
Revised: 29 September 2025
Accepted: 3 October 2025
First Online: 15 October 2025
Declarations
:
: C.S.G. has received consulting and/or speaker’s honoraria from Alexion Pharmaceuticals, Amgen, Amicus Therapeutics, Argenx, Bayer Vital, Hormosan Pharma, Immunovant, Janssen, Kyverna, Lupin Pharmaceuticals, Roche, Sanofi-Genzyme, and UCB outside the submitted work. B.B. received financial support by the German Federal Ministry for Education and Research, BMBF, German Competence Network Multiple Sclerosis (KKNMS). C.L. received a research grant by the German Federal Ministry for Education and Research, BMBF, German Competence Network Multiple Sclerosis (KKNMS), grant no.01GI1601I, and received consulting and speaker’s honoraria from Biogen Idec, Bayer Schering, Daiichi Sanykyo, Merck Serono, Novartis, Sanofi, Genzyme and TEVA. None of the other authors have any conflict of interest to disclose.
